1. Home
  2. AVTX vs CUE Comparison

AVTX vs CUE Comparison

Compare AVTX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVTX
  • CUE
  • Stock Information
  • Founded
  • AVTX 2011
  • CUE 2014
  • Country
  • AVTX United States
  • CUE United States
  • Employees
  • AVTX N/A
  • CUE N/A
  • Industry
  • AVTX Biotechnology: Pharmaceutical Preparations
  • CUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVTX Health Care
  • CUE Health Care
  • Exchange
  • AVTX Nasdaq
  • CUE Nasdaq
  • Market Cap
  • AVTX 88.4M
  • CUE 91.9M
  • IPO Year
  • AVTX 2015
  • CUE 2018
  • Fundamental
  • Price
  • AVTX $7.99
  • CUE $1.26
  • Analyst Decision
  • AVTX Strong Buy
  • CUE Strong Buy
  • Analyst Count
  • AVTX 4
  • CUE 5
  • Target Price
  • AVTX $33.00
  • CUE $5.00
  • AVG Volume (30 Days)
  • AVTX 59.5K
  • CUE 285.6K
  • Earning Date
  • AVTX 03-28-2025
  • CUE 03-10-2025
  • Dividend Yield
  • AVTX N/A
  • CUE N/A
  • EPS Growth
  • AVTX N/A
  • CUE N/A
  • EPS
  • AVTX N/A
  • CUE N/A
  • Revenue
  • AVTX $820,000.00
  • CUE $9,532,000.00
  • Revenue This Year
  • AVTX N/A
  • CUE $73.11
  • Revenue Next Year
  • AVTX N/A
  • CUE $11.02
  • P/E Ratio
  • AVTX N/A
  • CUE N/A
  • Revenue Growth
  • AVTX N/A
  • CUE 149.53
  • 52 Week Low
  • AVTX $4.18
  • CUE $0.45
  • 52 Week High
  • AVTX $34.46
  • CUE $2.45
  • Technical
  • Relative Strength Index (RSI)
  • AVTX 49.85
  • CUE 45.93
  • Support Level
  • AVTX $7.79
  • CUE $1.20
  • Resistance Level
  • AVTX $8.50
  • CUE $1.50
  • Average True Range (ATR)
  • AVTX 0.75
  • CUE 0.12
  • MACD
  • AVTX 0.16
  • CUE -0.02
  • Stochastic Oscillator
  • AVTX 63.53
  • CUE 16.67

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Share on Social Networks: